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The buccal tablets were formulated using the rate controlling polymers such as 
carbopol 974 P and Hydroxy propyl methyl cellulose K4M (HPMC K4M) or Sodium 
alginate in various ratios by D-Optimal design. Numerical optimization technique 
was applied to find out the best formulation by using the software Design Expert. 
All the formulations were evaluated and it was found that the carbopol 974P have 
good bioadhesion property but the HPMC K4M controls the drug release. In vitro 
drug release and release exponent were considered as dependent variables for 
optimization. The ideal formulation was undergone in vitro diffusion studies and 
stability studies.
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RESUMEN
Para la formulación de los comprimidos orales se usó la tasa de control de 
polímeros tales como carbopol 974P e hidroxipropilmetilcelulosa K4M (HPMC 
K4M) o alginato de sodio en varias proporciones, mediante el método de diseño 
D-Optimal. Se utilizó el programa Design Expert para aplicar la técnica de 
optimización numérica y encontrar la formulación óptima.  Después de evaluar 
todas las formulaciones, se encontró que el carbopol 974P tiene propiedades 
de bioadhesión buenas pero el HPMC K4M controla la liberación del fármaco. 
In vitro, la liberación del fármaco y el exponente de liberación se consideraron 
variables dependientes para la optimización. La formulación ideal se realizó 
mediante estudios de difusión y de estabilidad in vitro.
PALABRAS CLAVE: Comprimido oral, Diclofenaco sódico, Diseño D-Optimal, 
Optimización.
INTRODUCTION
Among the various transmucosal routes, buccal mucosa 
has excellent accessibility, an expanse of smooth muscle 
and relatively immobile mucosa, hence suitable for 
administration of retentive dosage forms. Direct access to 
the systemic circulation through the internal jugular vein 
by passes drugs from the hepatic first pass metabolism 
leading to high bioavailability. Other advantages such also 
enzymatic activity, suitability for drugs or excipients that 
mildly and reversibly damages or irritates the mucosa, 
painless administration, easy drug withdrawal, facility 
to include permeation enhancer/enzyme inhibitor or pH 
modifier in the formulation and versatility in designing as 
multidirectional or unidirectional release systems for local 
or systemic actions etc, opts buccal adhesive drug delivery 
systems as promising option for continued research.1,2
Mucoadhesive drug delivery system which utilize the 
property of bioadhesion of certain polymers, which become 
adhesive on hydration. Bioadhesion is an interfacial 
phenomenon in which two materials, at least one which 
is biological, are held together by means of interfacial 
force.3 Within the oral mucosal cavity, the buccal region 
offers an attractive route of administration for systemic 
drug delivery. The mucosa has a rich blood supply and it 
is relatively permeable.4 Permeability of the buccal mucosa 
is 4-4000 times greater than that of the skin. As indicated by 
a wide range in this reported values, there are considerable 
differences in permeability between different regions of the 
oral cavity. The saliva pH ranges from 5.8 to 7.4 depending 
on the flow rate. Absorption is maximum at the un-ionized 
form of drug in salivary pH. Systemic availability of drugs 
that bind to oral mucosa is poor.5,6 Faster turnover of buccal 
mucosal epithelium (3-8 days) relative to the skin (about 30 
days) may affect drug absorption by continually changing 
permeability characteristics. Conventionally used buccal 
dosage forms have serious drawbacks like the salivary 
scavenging effect. In the present investigation to prevent 
this effect by designing a mucoadhesive dosage form that 
delivers the drug unidirectionally and improve the rate 
of penetration of diclofenac sodium by the inclusion of 
penetration enhancer like sodium lauryl sulphate.6-8. 
Diclofenac sodium is a non steroidal anti-inflammatory 
analgesic with potent cyclooxygenase inhibition activity 
and also commonly used for pain control and the treatment 
of rheumatic diseases. Diclofenac sodium has biological 
half life of 2 h and it absorbs throughout the intestinal tract. 
Diclofenac is 100% absorbed after oral administration. 
However, due to first pass metabolism, only about 50% of 
the absorbed dose is systemically available.8 The complete 
100% absorption classifies diclofenac as highly permeable. 
To prolong the drug release and to reduce dosing 
frequency, a suitable formulation was required with a 
controlled rate to treat dental pain and inflammation. In the 
present study, controlled release buccoadhesive tablets of 
Diclofenac sodium mainly for the treatment of odontalgia 
were designed using hydrophilic polymers such as HPMC 




Diclofenac sodium was donated by Novartis pharmaceutical 
Ltd (Mumbai, India). HPMC K4M by Colorcon Asia, india. 
Carbopol 934 P and sodium alginate was received as gift 
sample from Strides Arco labs LTD (Bangalore, India). 
Mannitol and Sodium lauryl sulphate was purchased from 
S. D. fine Chem. LTD (Mumbai, India). All other chemicals 
and reagents used were of analytical grade and purchased 
from Merck Ltd., India. 
Methods: 
Experimental design: D-Optimal design was applied 
using the software Design-Expert software (Stat-Ease Inc, 
Minneapolis, USA). Factors taken as A & B. ‘A’ is the HPMC 
K4M or Sodium alginate, ‘B’ is the Carbopol 934P9.
Fourier Transform Infrared Spectroscopy (FT-IR): Physical 
mixtures of drug and excipients were prepared to study 
the drug polymer interaction. Drug polymer interaction 
studies were carried out using FT-IR spectrophotometer 
(Bruker, Tensor-27).10,11
Buccoadhesive tablets preparation: Buccoadhesive belayed 
tablets are prepared by direct compression method in two 
steps. Diclofenac sodium was mixed manually in glass 
mortar with different ratios of HPMC K4M or Sodium 
alginate and Carbopol 934 P as mucoadhesive polymers 
and mannitol as diluents and all other ingredients except 
magnesium stearate (Table 1) for 10 min. The blend was 
lubricated with magnesium stearate for 4 min and then 
compressed by using 10 mm flat-faced punches. The upper 
punch was raised and the backing layer of ethyl cellulose 
(20 mg) was then added on the above compact and the two 
layers were compressed in to bilayered tablets. The tablets 
were compressed using a Cadmach rotary tablet machine 
(Cadmach Machinery, India). The weight variation of the 
tablets was determined using a digital balance (Shimadzu 
Japan) and thickness with a screw gauge.12
Powder flow properties: The angle repose, bulk density, 
porosity and carr’s index for all the formulations were 
determined.13
Evaluation of Buccoadhesive Tablets:
Physical properties of tablets: The thickness, hardness, 
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friability and weight uniformity of all the formulations 
were analyzed as per USP standards.13
Assay of Diclofenac sodium: Ten tablets were accurately 
weighed and powdered. A quantity of the powder 
equivalent to 100 mg of Diclofenac sodium was weighed 
accurately and extracted in 100 ml methanol by shaking 
for 20 min. After filtration through whatmann filter paper 
no.1 and sufficient dilution with methanol, samples were 
analyzed spectrophotometrically at 283 nm. Amount of 
drug present was determined from the calibration curve of 
Diclofenac sodium in methanol.14
In vitro release studies: The drug release rate from buccal 
tablets was studied using the USP 28 type II dissolution 
test apparatus (Electrolab, India). To release the drug 
from one side the impermeable backing layer side of the 
tablet was fixed to a 2x2 cm glass slide with a solution 
of cyanoacrylate adhesive. Then it was placed in the 
dissolution apparatus. The dissolution medium was 500 
mL of phosphate buffer pH 6.8. The release was performed 
at 37±0.5°C, with a rotation speed of 50 rpm. Samples of 
5mL were collected at different time intervals up to 8 h and 
analyzed spectrophotometrically.
Stability Study in Human Saliva: The stability study of 
optimized buccal adhessive tablets was performed in 
natural human saliva. The human saliva was collected 
from humans (age18-50 years). Buccal tablets were placed 
in separate petridishes containing 5mL of human saliva and 
placed in a temperature controlled oven (Hicon, Groover 
Enterprises, Delhi, India) at 37°C± 0.2°C for 6 h. At regular 
time intervals (0, 1, 2, 3, and 6 h), the tablets were examined 
for changes in color and shape, collapsing of the tablets, 
and drug content.12
Analysis of Release Mechanism: The in vitro release data 
were treated to different equations and kinetic models 
to explain the release kinetics of Diclofenac sodium from 
the buccal tablets. The kinetic models were used a zero 
order equations, first order equations. Higuchi release, 
Korsmeyar and Peppas models.15,16. 
Tissue isolation: Porcine buccal tissue from domestic pigs 
was obtained from a local slaughter house and used within 
2 h of slaughter. The tissue was stored in Krebs buffer pH 
7.4 at 4°C after collection. The epithelium was separated 
from the underlying connective tissue with a surgical 
technique and the delipidized membrane was allowed 
to equilibrate for approximately 1 h in receptor buffer to 
regain lost elasticity.16,17
In vitro drug permeation through porcine buccal 
membrane: The diffusion study was carried out by using 
a K-C diffusion Cell. This study from buccal tablets of 
different formulations through porcine buccal membrane 
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Table 1. Master formula (Quantity for one tablet)
Each formula also contains:  Diclofenac sodium 50 mg; Sodium Lauryl Sulpahte 5 mg; Magnesium stearate 2 mg; Aspartame 
5 mg, Ethyl cellulose 20 mg.
Formulation code HPMC K4M (mg) Carbopol 934 P (mg) Sodium alginate(mg) Mannitol (mg)
F1 20 20 - 78
F2 40 20 - 58
F3 60 20 - 38
F4 20 35 - 63
F5 40 35 - 43
F6 60 35 - 23
F7 20 50 - 48
F8 40 50 - 28
F9 60 50 - 8
F10 - 20 20 78
F11 - 20 40 58
F12 - 20 60 38
F13 - 35 20 63
F14 - 35 40 43
F15 - 35 60 23
F16 - 50 20 48
F17 - 50 40 28
F18 - 50 60 8
was mounted over a K-C Cell whose internal diameter is 
2.1 cm and a buccal tablet was placed over it. Reservoir 
compartment containing 25 ml phosphate buffer (pH 7.4) 
and donor compartment containing phosphate buffer 
(pH 6.8). Diffusion cell was thermo stated at 37 ±1°C and 
stirred at a rate of 50 rpm. Sink condition was maintained 
throughout the study. Aliquots of 1 ml of sample were 
withdrawn with pipette at every 1 h time intervals up to 
12 h with equal volume of phosphate buffer. Aliquots were 
diluted and analyzed spectrophotometrically at 277 nm 
and the cumulative amount of drug diffused at various 
time intervals was calculated.16
Surface pH: A combined glass electrode was used for this 
purpose. The buccal tablets were kept in contact with 0.5 
ml of distilled water for 1 h. pH was noted by bringing the 
electrode near the surface of the formulations and allowing 
it to equilibrate for 1 min.18,19
Ex vivo Mucoadhesive Strength: Bioadhesive strength of 
the buccal tablets was measured on the “Modified Physical 
Balance method”. The method used porcine buccal 
membrane as the model mucosal membrane. The two sides 
of balance were balanced with 20 g weight on the right hand 
side. A pieces of fresh membrane was hold by the help of 
pins, which was then filled with isotonic phosphate buffer 
(pH 6.8) kept at 37± 1º C, such that the buffer solution just 
reaches the surface of mucosal membrane, keep it moist, 
this was then kept below the left hand setup of the balance. 
The test tablet was glued with adhesive to a rubber block 
hanging on the left side and the balance beam raised with 
the 20 g weight on the right pan was removed off the 
weight. The balance was kept in this position for 5 minutes 
and then slowly added in the right pan. The addition of 
weight was stopped as soon as the detachment of two 
surfaces was obtained. The excess weight in the pan that 
is total weight minus 20 g is the force required to separate 
the tablet from the mucosa was measured. This gave the 
bioadhesive strength of the buccal tablet in grams.20,21
Swelling Study: Agar (5%, m/V) was dissolved in hot 
water. It was transferred into petridishes and allowed to 
solidify. Six buccal tablets from each formulation were 
placed in a vacuum oven over night prior to the study to 
remove moisture, if any, and laminated on one side with 
a water impermeable backing membrane. They were then 
placed on the surface of the agar and incubated at 37°C for 
1 h. Then the tablets were removed and weighed and the 
percentage of moisture absorption was calculated.16
Ex vivo Mucoadhesion Time: The in vitro residence time 
was determined using a locally modified USP disintegration 
apparatus. The disintegration medium was 800 ml isotonic 
phosphate buffer solution pH 6.8, maintains at 37°C ± 1°C. 
A segment of porcine buccal mucosa was glued to glass 
slide, attached to glass slab which is vertically attached 
to apparatus. The buccal tablet was hydrated from one 
surface using little amount of isotonic phosphate buffer 
solution, and then the hydrated surface was brought into 
the contact with the mucosal membrane. The glass slab was 
vertically fixed to the apparatus and allows moving up and 
down so that the tablet was completely immersed into the 
solution at lowest point and was out at highest point. The 
time necessary for complete erosion or detachment of the 
tablet from the mucosa surface were recorded.22
Optimization: In the numerical optimization techniques, 
the desirability approch was used to generate the optimum 
settings for the formulation. For the optimized formulation, 
the drug release at 2 h, 4 h, 8 h, release exponent(n) were 
kept in target. The drug release target was kept according 
to the USP standards and release exponent(n) kept in 
maximum value. The optimization process was carried out 
using Design-Expert software (Stat-Ease Inc, Minneapolis, 
USA). The responses such as drug release at 2 h, 4 h, 8 h 
represented by R1, R2, R3 and release exponent(n) by R4.   
Regression analysis: The response parameters were 
statistically analyzed by applying one way ANOVA at 
0.05 levels using commercially available software Design-
Expert software (Stat-Ease Inc, Minneapolis, USA). The 
individual parameters were evaluated using the F test and 
Linear, 2FI, Quadratic models were generated for each 
response parameter using the multiple linear regression 
analysis (MLRA) equation:
R = b0 + b1 A+ b2B + b3AB + b4A2 + b5B2 + b6AB2 + b7A2B       
Where, R is the level of measured response, b0 is the 
intercept of the arithmetic mean response of the 13 runs, A 
and B are the coded level of the independent variables. The 
AB is the interaction term, show how response changes 
when two factors are simultaneously used. A2, B2 are 
quadratic terms of the independent variables to evaluate 
the nonlinearity.
Stability studies: Stability studies were carried out on the 
buccal tablet of most satisfactory as per ICH Guidelines 
Q1C. The most satisfactory formulation stored in sealed in 
aluminum foil. These were stored at 30oC ± 2ºC, 65% ± 5% 
RH and 40oC ± 2ºC, 75% ± 5% RH  for 2 months. Tablets 
were evaluated for physical characteristics, mucoadhesive 




(Final weight - Initial weight) × 100
 Initial weight
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Table 2.  Mathematical equation of drug release
In vitro drug release time
Mathematical equation in terms of actual factors
Formulation F1 to F9 Formulation F10 to F18
2 h R1 = 26.96 + 11.66 x A - 5.21 x B R1 = 33.01+ 9.28 x A - 3.21 x B
4 h R2 = 45.95 + 18.16 x A - 7.02 x B R2 = 55.05 + 15.24 x A 5.93 x B
8 h   R3 = 75.24 + 20.09 x A - 5.36 x B R3= 79.93 + 16.99 x A - 5.01 x B
RESULTS AND DISCUSSION
The FT-IR studies it was revealed that there was no drug and 
excipient interaction. The spectra are given in Fig.1. The powder 
flow properties were found to be good. The hardness, friability, 
thickness, weight and drug content of prepared buccal tablets 
were found to be in the range of 3-4 kg/cm2, 0.12-0.65% w/w, 
1.5-2 mm, 198-203 mg and 98.09-100.94% respectively. 
Surface pH: The  surface  pH  of  all  the  formulations  was 
found  to  be within neutral  pH with ±1 and  hence,  these 
formulations  should  not  cause any  irritation  in  the  buccal 
cavity.
In vitro dissolution study: In vitro drug release study after 2 h 
(R1), 4 h (R2), 8 h (R3): The cumulative amount of drug released 
in all the formulations ranges from 19.65 to 47.35%, 32.44 to 
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Figure 1. FT-IR Spectra of physical mixtures of drug & polymers. 
79.25% and 56.25 to 100% in 2 h, 4 h and 8 h respectively. The 
drug release was affected by the concentration of the polymers 
such as HPMC K4M and sodium alginate. The concentration 
of Carbopol 934P also controls the drug release. The effect 
of release rate controlling polymers can be explained by 
mathematical equation in terms of actual factors (Table 2). 
The in vitro drug release profile of all the formulations are 
given in Fig. 2A, 2B & 2C.    
The effect of A and B can be further elucidated with the 
help of 3D surface plot (Fig.3A-3F). It shows the drug 
release directly affects the concentration of factor ‘A’. If 
the concentration of factor ‘A’ increases the drug release 
decreases proportionally but the factor ‘B’ shows non linear 
effect. It clearly shows the influence of rate controlling 
polymer (Factor A) on the drug release. 
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Stability studies in human saliva: The stability studies in 
human saliva shows no colour change and the tablets was 
not collapsed. The thickness and diameter of the tablets 
were increased with time and the drug content was with 
in the limit.
Analysis of release mechanism: In the case of optimized 
formulation (F5) when the data were plotted according 
to the first-order equation, the formulations showed a 
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Figure 2a. Dissolution profile of formulation F1-F6
Figure 2b. Dissolution profile of formulation F7-F12
Figure 2c. Dissolution profile of formulation F13-F18
comparatively poor linearity, with regression value of 0.969; 
whereas the regression value for zero-order equation was 
0.990, which indicated that drug release was independent 
of drug concentration. The ‘n value’ for Peppas model was 
found to be in between 0.45 and 0.89, indicates that the 
drug released from the formulation by anomalous (non-
Fickians) mechanism and also the maximum ‘n value’ 
observed in F5 (table 3).
ANOVA: The result of ANOVA demostrate all the 
independent variables were found to be significant for 
response R1, R2, R3 & R4. The linear  model were found 
to be significant for all responses. Above result indicate the 
factors A&B (Factor A is HPMC K4 or Sodium alginate, 
Factor B is Carbopol 934P) play an important role in the 
formulation.
In vitro drug permeation: The in vitro permeation studies 
shown that the released drug permeates the buccal 
membrane linearly. Good correlation was obtained 
between in vitro drug release and in vitro drug permeation 
study with the correlation coefficient of 0.994 (Fig.4).
Ex vivo mucoadhesive strength: The mucoadhesive 
strength of the formulations were directly proportional to 
the concentration of HPMC or Sodium alginate. Compare 
to the sodium alginate the HPMC K4M containing 
formulations shown good mucoadhesive strength. The 
carbopol 934 P has the main effect in mucoadhesive 
strength which increases the strength with increase in 
concentration. Results are given in table 4.
Swelling study: The swelling index of all the formulations 
were increased with increase in the concentration of 
cabopol, HPMC or sodium alginate. The HPMC is a 
swellable rate controlling polymer, it absorbs the moisture 
and swells according to its concentration. In the case of 
sodium alginate based formulation, the swelling with 
erosion was taken place. The results are given in table 4.   
Ex vivo mucoadhesion time: The mucoadhesion time 
of the HPMC K4M based formulations increases with 
increase in concentration of the Carbopol and HPMC. 
The mucoadhesion time of the sodium alginate based 
formulations also increases with increase in concentration 
of the carbopol and sodium alginate. From the observations 
(table 4) it was clear that the Carbopol 934 P provides better 
mucoadhesion property than HPMC and sodium alginate.
Optimization: It was concluded that the formulation F5 is 
the most satisfactory formulation for the buccal delivery 
of Diclofenac sodium. A good releationship between 
the experimental and predicted values (Table 5), which 
confirms the practicability and validity of the model.
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Table 3a. 3D surface plot showing the effect of 
factor A and factor B on drug release after 2 h in 
formulation F1- F9
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Table 3b. 3D surface plot showing the effect of 
factor A and factor B on drug release after 2 h in 
formulation F10- F18
Table 3c. 3D surface plot showing the effect of 
factor A and factor B on drug release after 4 h in 
formulation F1- F9
Table 3d. 3D surface plot showing the effect of 
factor A and factor B on drug release after 4 h in 
formulation F10- F18
Table 3e. 3D surface plot showing the effect of 
factor A and factor B on drug release after 8 h in 
formulation F1- F9
Table 3f. 3D surface plot showing the effect of 
factor A and factor B on drug release after 8 h in 
formulation F10- F18
Design, Development and Optimization of Buccal bioadhesive tablets of diclofenac sodium for the treatment of odontalgia
Ars Pharm. 2011; 52(2): 05-13.
12
Table 3. Summary of drug release kinetics of formulations
Kinetic profile of formulation
Korsmeyer Peppas Zero order First order Higuchi
n KKP R2 K0 R2 K R2 KH R2
F1 0.687 12.13 0.994 13.91 0.960 -0.136 0.649 39.55 0.979
F2 0.781 14.36 0.994 9.030 0.989 -0.276 0.971 26.99 0.951
F3 0.782 13.57 0.995 7.797 0.992 -0.361 0.980 23.20 0.945
F4 0.680 14.22 0.998 11.84 0.965 -0.873 0.601 36.47 0.984
F5 0.809 16.21 0.990 8.272 0.995 -0.811 0.969 24.43 0.934
F6 0.774 15.76 0.996 7.315 0.983 -0.376 0.997 22.11 0.966
F7 0.797 16.98 0.990 10.52 0.977 -0.462 0.980 31.97 0.971
F8 0.798 15.43 0.998 7.919 0.986 -0.623 0.997 23.85 0.963
F9 0.796 13.25 0.993 6.804 0.986 -0.562 0.993 20.45 0.959
F10 0.702 14.33 0.995 16.49 0.969 -0.746 0.844 42.52 0.974
F11 0.680 16.10 0.998 9.479 0.965 -0.451 0.994 29.17 0.984
F12 0.577 15.22 0.968 8.367 0.954 -0.672 0.992 25.88 0.983
F13 0.686 17.11 0.998 13.75 0.966 -0.346 0.781 39.07 0.983
F14 0.690 14.27 0.998 9.051 0.965 -0.267 0.998 27.84 0.983
F15 0.573 15.87 0.973 7.774 0.949 -0.167 0.991 24.15 0.986
F16 0.576 15.01 0.969 10.65 0.954 -0.107 0.975 32.99 0.983
F17 0.570 14.52 0.970 8.095 0.955 -0.271 0.993 25.06 0.985
F18 0.574 15.28 0.969 7.757 0.954 -0.211 0.991 24.01 0.984
Drug release exponents (n), Korsmeyer Peppas release constant (KKP), Correlation coefficient (R2) of different models, 
Zero order release rate constants (K0), First order release rate constant (K), Higuchi release rate constant (KH).
Table 4. Mucoadhesive properties of buccal tablets
Formulation Code Mucoadhesive strength (g) Mucoadhesion time (h) % Swelling index
F1 17.34 ± 1.10 10.10 ± 0.14 16.11 ± 1.14
F2 18.32 ± 1.24 10.45 ± 0.20 18.24 ± 1.11
F3 20.17 ± 1.30 11.14 ± 0.22 20.35 ± 0.57
F4 22.43 ± 1.02 11.30 ± 0.15 20.13 ± 1.15
F5 24.45 ± 1.35 12.10 ± 0.20 24.18 ± 1.20
F6 25.36 ± 1.30 12.30 ± 0.18 26.20 ± 1.05
F7 28.33 ± 1.13 12.55 ± 0.25 26.04 ± 0.98
F8 29.40 ± 1.25 13.15 ± 0.15 28.15 ± 1.12
F9 33.55 ± 1.40 13.40 ± 0.24 30.05 ± 1.25
F10 16.23 ± 1.15 9.05 ± 0.16 15.20 ± 1.02
F11 16.54 ± 1.21 9.25 ± 0.22 17.31 ± 1.22
F12 17.56 ± 1.05 9.45 ± 0.26 19.20 ± 1.32
F13 20.23 ± 1.19 10.45 ± 0.30 19.25 ± 1.21
F14 22.54 ± 1.34 11.05 ± 0.25 21.20 ± 1.22
F15 23.11 ± 0.95 11.20 ± 0.20 22.15 ± 1.08
F16 24.52 ± 1.22 11.55 ± 0.18 22.32 ± 0.78
F17 25.25 ± 1.34 12.10 ± 0.15 23.43 ± 1.32
F18 26.20 ± 1.12 12.24 ± 0.10 25.33 ± 1.27
Table 5. Comparison of experimented and predicted values of optimized formulation using Design expert software
Optimized formula F5
Dependable variables
Drug release at 2 h Drug release at 4 h Drug release at 8 h Release exponent
Predicted 21.7533 38.9333 69.55 0.767111
Experimental 19.65 37.23 69.55 0.809
Edavalath S, Rao BP. 
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Stability studies: After the 6 months storage of formulation 
F5, values of all parameters like hardness, diameter, 
thickness, % drug content, friability were evaluated 
periodically and found to be almost similar to the initial 
values. The drug dissolution and permeation profile were 
similar to the initial profile and also no changes in the 
physical appearance. So it can be said that formulation is 
stable. Data is not shown.
CONCLUSIONS
The observed independent variables were found to be very 
close to predicted values of optimized formulation which 
demostrates the feasibility of the optimization procedure 
in successful development of Buccal bioadhesive tablets of 
Diclofenac sodium (50 mg) by using HPMC K4M (40mg) as 
release rate controlling polymer and Carbopol 934 P(35mg)
as mucoadhesive polymer. The stability studies revealed 
that optimized formulation is stable.
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